UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant $extsf{ extsf{ iny line integral}}$

Filed by a party other than the Registrant $\ \square$

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- □ Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material under §240.14a-12

ALIGOS THERAPEUTICS, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ☑ No fee required
- □ Fee paid previously with preliminary materials

□ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



Aligos Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials

Stockholders Meeting to be held on July 20, 2023


For Stockholders of record as of May 23, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/ALGS

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before July 10, 2023.

To order paper materials, use one of the following methods.





When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.



paper@investorelections.com

If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquires should be included with your e-mail requesting material.

Aligos Therapeutics, Inc.

Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

Meeting Type: Annual Meeting of Stockholders Date: Thursday, July 20, 2023

Time: 8:00 AM, Pacific Time

Place: Annual Meeting to be held live via the internet -

Please visit www.proxydocs.com/ALGS for more details.

SEE REVERSE FOR FULL AGENDA

Aligos Therapeutics, Inc. Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ON PROPOSALS 1 AND 2

PROPOSAL

1. The election of three Class II directors to hold office until our 2026 annual meeting of stockholders.

1.01 Jack B. Nielsen

1.02 Bridget Martell, M.A., M.D.

1.03 Carole Nuechterlein, J.D.

- To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of Ernst &Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
- 3. The transaction of such other business as may properly come before the meeting.